EndoEvolution develops advanced automated suturing devices for minimally invasive surgery, including the commercially available reusable Endo360° MIS suturing device and the in-development 5mm EndoTransformer™. Its products use curved needles to replicate traditional intracorporeal stitching and tying and are offered with a full complement of standard sutures. The company reports its Endo360° device is in production and ready for market and positions its technology as delivering clinical advantages and cost-savings to hospitals. EndoEvolution’s devices have demonstrated clinical effectiveness across bariatric, colorectal, general surgery, gynecology, and urogynecology. In May 2012 Edwards Lifesciences licensed EndoEvolution’s suturing technology for use in cardiac surgery. Founder Jerry Brecher will remain involved with product development and clinical initiatives while the new CEO leads commercialization efforts. EndoEvolution develops next-generation automated suturing devices for minimally invasive surgery, including the Endo360° and the 5mm EndoTransformer. Its Endo360° is cleared by the FDA and is the company’s initial product slated for commercial launch. The EndoTransformer is in late-stage development and described as the first 5mm curved-needle suturing device for MIS. Both devices use curved needles to replicate traditional hand-suturing and intracorporeal knot-tying, and the company emphasizes reusable instruments that reduce hospital costs. EndoEvolution cites more than 1.5 million U.S. MIS procedures requiring suturing annually, implying a market worth hundreds of millions of dollars. The company also highlights environmental benefits from reusable stainless-steel devices versus single-use disposable plastics.

Total raised

$8M

Funding rounds

2

Latest round

Series C

Latest activity

Apr 2013